Back to search

Article

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value on treatment-free remission in chronic myeloid leukemia patients treated with imatinib

2023-04-06

Abstract excerpt

<title>Abstract</title> <p>Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that reflect allele arrangement of genes encoding drug transporters associated with treatment response. In previous work, we identified SNP rs460089...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0c1f0862-918a-54dc-b6dd-05902a071be3
DOI
10.21203/rs.3.rs-2770615/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value on treatment-free remission in chronic myeloid leukemia patients treated with imatinibDOI 10.21203/rs.3.rs-2770615/v1
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibSemantic proximity
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinibSemantic proximity
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.Semantic proximity
OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.Semantic proximity
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Semantic proximity
hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Semantic proximity
Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.Semantic proximity
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.Semantic proximity
Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.Semantic proximity
Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.Semantic proximity
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.Semantic proximity
Factors affecting the response to tyrosine kinase inhibitors in chronic myeloid leukaemiaSemantic proximity
Select a neighboring publication to make it the new centre.